| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | GDC-0941 | FIMM | pan-cancer | AAC | 0.25 | 0.2 |
| mRNA | regorafenib | CTRPv2 | pan-cancer | AAC | 0.051 | 0.2 |
| mRNA | valdecoxib | CTRPv2 | pan-cancer | AAC | 0.048 | 0.2 |
| mRNA | tacrolimus | CTRPv2 | pan-cancer | AAC | 0.047 | 0.2 |
| mRNA | SL 0101-1 | GDSC1000 | pan-cancer | AAC | -0.048 | 0.2 |
| mRNA | MS-275 | gCSI | pan-cancer | AAC | -0.071 | 0.2 |
| mRNA | SID 26681509 | CTRPv2 | pan-cancer | AAC | -0.05 | 0.2 |
| mRNA | Vandetanib | FIMM | pan-cancer | AAC | 0.24 | 0.2 |
| mRNA | decitabine:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.041 | 0.2 |
| mRNA | KW-2449 | CTRPv2 | pan-cancer | AAC | 0.04 | 0.2 |